Spontaneous bilateral haemothorax with haemopericardium secondary to rivaroxaban

J Clin Pharm Ther. 2020 Oct;45(5):1175-1178. doi: 10.1111/jcpt.13116. Epub 2020 Feb 5.

Abstract

What is known and objective: Although the risk of major bleeding with non-vitamin K antagonist oral anticoagulant (NOAC) is low, life-threatening bleeding can occur.

Case summary: We report a case of an 81-year-old female with deep vein thrombosis who developed bilateral spontaneous haemothorax and haemopericardium after rivaroxaban therapy. Diagnostic thoracentesis revealed a grossly bloody pleural effusion. She was treated with factor eight inhibitor bypassing agent, but the result was not satisfactory.

What is new and conclusion: To our knowledge, this is the first case report of a concomitant presentation of spontaneous bilateral haemothorax and haemopericardium due to rivaroxaban use. This case highlights the potential risk of major haemorrhagic complication of NOAC, which could be life-threatening and require emergent reversal.

Keywords: factor Xa inhibitors; haemopericardium; non-vitamin K antagonist oral anticoagulants; rivaroxaban; spontaneous haemothorax.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Factor Xa Inhibitors / administration & dosage
  • Factor Xa Inhibitors / adverse effects*
  • Female
  • Hemothorax / chemically induced*
  • Hemothorax / diagnosis
  • Humans
  • Pericardial Effusion / chemically induced*
  • Pericardial Effusion / diagnosis
  • Rivaroxaban / administration & dosage
  • Rivaroxaban / adverse effects*
  • Venous Thrombosis / drug therapy

Substances

  • Factor Xa Inhibitors
  • Rivaroxaban